BC Innovations | Dec 12, 2019
Tools & Techniques

New hepatic stellate cell subset drives liver fibrosis

A team including University of Edinburgh and Gilead researchers has used single-cell sequencing to zero in on a pathogenic subpopulation of hepatic stellate cells that could be targeted to treat liver fibrosis. Reported in a...
BC Innovations | Jan 3, 2019
Distillery Therapeutics


INDICATION: Sarcoma In vitro , mouse and pig studies identified an RXR agonist that could help treat soft tissue sarcoma (STS). In silico screening of a small molecule library for compounds predicted to bind RXR, followed...
BC Innovations | Jul 25, 2018
Distillery Therapeutics


INDICATION: Melanoma Cell culture and mouse studies suggest inhibiting RXR could help treat melanoma. In a human melanoma cell line, the combination of a tool compound RXR inhibitor and Mekinist trametinib decreased colony formation and...
BC Extra | Jul 13, 2018
Preclinical News

RXR a potential minimal residual disease target in melanoma

New research into the biology of solid tumor minimal residual disease (MRD) has revealed retinoid X receptor (RXR) as a potential target to delay development of drug resistance in melanoma. Cancer relapse is driven by...
BC Innovations | Oct 27, 2016
Distillery Therapeutics


INDICATION: Cancer; colorectal cancer; cutaneous T cell lymphoma (CTCL) In vitro and cell culture studies identified agonists of RXR heterodimerization that could help treat colorectal cancer, CTCL and other cancers without causing the metabolic and...
BC Innovations | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
BC Innovations | Feb 25, 2016

Changing the channel

Having helped expose the reproducibility crisis about five years ago, Amgen Inc. is staying at the forefront of the issue with its support of F1000Research , an open-science platform to let researchers check each other's data....
BC Week In Review | Aug 17, 2015
Company News

Mylan sales and marketing update

Mylan launched bexarotene 75 mg capsules in the U.S. to treat cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene is a generic version of...
BC Innovations | Jul 23, 2015
Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor (PPAR) α; retinoid X receptor (RXR)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and mouse studies suggest agonists of PPARα and its co-activator RXR could help treat AD. In a mouse model of AD, PPARα knockout increased β amyloid (Aβ) deposition...
BC Innovations | Jul 16, 2015
Distillery Therapeutics

Therapeutics: Retinoid X receptor (RXR)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and mouse studies suggest combining docosahexaenoic acid (DHA) and the RXR agonist bexarotene could help treat AD. In primary mouse glial cells and a transgenic mouse model of...
Items per page:
1 - 10 of 105